Australia seems poised to gain access to innovative therapy for obesity: Retatrutide. This new dual agonist – targeting on both GLP-1 and GIP receptors – shows promising outcomes in clinical trials, pointing to substantial reductions in weight. While approval is pending with Australian regulators, a number of Australians dealing with weight-rel